CardioSignal enters US market, with a focus on accelerating accessibility to remote cardiac care
CardioSignal Inc. announces US market entry with its novel technology for remote cardiac care, focusing on improving earlier detection of atrial fibrillation and heart failure with a smartphone.
CardioSignal Inc. is strongly positioned to enter the United States market with new collaborations, accolades, and team members. CardioSignal’s technology is the first of its kind to be able to combine several heart disease detection capabilities under one method and enable its use in primary care and home monitoring. For serving healthcare professionals with remote cardiac care solutions, CardioSignal is working closely with the FDA to enable the launch of the first remote care solution in the US during the first quarter of 2023.
Recently, CardioSignal announced its first US partnership in remote cardiac care with JISEKI Health and achieved new levels of scientific evidence from clinical trials. As announced on September 30, 2022, the clinical study conducted with Stanford University and University Hospitals in Turku and Helsinki demonstrated a high accuracy for digital cardiac biomarkers in heart failure, even compared to existing clinical methods.
In September 2022, CardioSignal won the American Heart Association’s EMPowered to Serve program grant award for the Bay Area, California(1), and was accepted as a member of the Mayo Clinic’s Innovation Exchange program.
CardioSignal also welcomes Ursula Burns, the former Chairwoman and CEO of Xerox Corporation and VEON, Ltd., to its Board of Directors. With her vast global experience and network, the company is even better positioned to enter the US market to digitize cardiac care with a particular focus on the underserved at-risk population.
“Solving the growing burden of heart disease, and the disparity that persists within, requires strong leadership. I am honored to welcome Ursula Burns to our Board of Directors to help us scale this innovation in healthcare. Our technology represents a future where a one-minute measurement from the chest with a modern smartphone can direct patients to care earlier and enable the initiation of lifesaving treatments,” said CEO, cardiologist Juuso Blomster.
“We must be aware of the fundamental disparity in access to care so that we can create a more inclusive health care system. The capability to bring heart disease detection to smartphones is pivotal for accessibility and it addresses many of the gaps that exist in the wider adoption of digital health. I am thrilled to join CardioSignal’s Board of Directors and be part of this important journey,” Ursula Burns said.
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases with digital cardiac biomarkers. The CardioSignal technology utilizes motion sensors to non-invasively measure chest movements and determine cardiac motion and function. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal Inc is a subsidiary of a Finnish health technology company Precordior ltd. cardiosignal.com / us.cardiosignal.com.
About Ursula Burns
Ursula Burns served as Chairwoman of the Board of Directors and CEO of Xerox Corporation and VEON, Ltd. Currently, Ms. Burns serves several public, private, and non-profit boards and counsels the United States government on key policies. She serves on the Board of Directors of Uber Technologies, Inc., Endeavor Group Holdings, Inc., ExxonMobil Corporation, and IHS Holdings. She is also a member of the Mayo Clinic and the Metropolitan Museum of Art’s Board of Trustees. Ms. Burns was also appointed by President Obama to lead the White House national program on Science, Technology, Engineering and Math (STEM).
About heart failure:
Currently, heart failure diagnostics focuses on blood biomarkers requiring specialized interpretation. This makes heart failure checkups difficult to scale and to provide regularly to at-risk individuals. For example, there are over 30 million diabetes II patients(2) in United States who would benefit from annual screening(3). The delay in diagnosing heart failure is evident: approximately a third of heart failure patients learn about their condition once in acute care despite having symptoms in the prior 6 months(4). Racial minorities, individuals in rural areas, and lower socio-economic groups are particularly impacted by disparities in heart health.
Further information
CEO Juuso Blomster, juuso.blomster@cardiosignal.com
President Tero-Pekka Alastalo, CardioSignal Inc (Partnerships), tpa@cardiosignal.com. tel. +1 (650) 285-8564
Communication Director Juulia Simonen, juulia.simonen@cardiosignal.com, tel. (+358) 503059018
Inquiries for Ms. Ursula Burns:
Tiffany Woo, Chief of Staff, tiffany.woo@teneo.com
1. EMPowered to Serve is an accelerator that supports social entrepreneurs and organizations by funding local solutions to social determinants of health.
2. CDC 2021: www.cdc.gov/diabetes
3. Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022 May, 79 (17) e263–e421
4. T. Sandhu et al, Disparity in the Setting of Incident Heart Failure Diagnosis, Circulation: Heart Failure (2021); vol. 14, No. 8.
